Work

Advances in the Management of Treatment-Resistant Depression

Year: 2010

Type: article

Abstract: Treatment-resistant depression (TRD) is a prevalent, disabling, and costly condition affecting 1%-4% of the U.S. POPULATION: Current approaches to managing TRD include medication augmentation (with lithium, thyroid hormone, buspirone, atypical antipsychotics, or various antidepressant medications), psychotherapy, and ECT. Advances in understanding the neurobiology of mood regulation and depression have led to a number of new potential approaches to managing TRD, including medications with novel mechanisms of action and focal brain stimulation techniques. This review will define and discuss the epidemiology of TRD, review the current approaches to its management, and then provide an overview of several developing interventions.

Source: FOCUS The Journal of Lifelong Learning in Psychiatry

DOI: 10.1176/foc.8.4.foc488

Author: Paul E. Holtzheimer

Institution: Emory University

Language: English

Topic: Treatment of Major Depression

Subfield: Pharmacology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Dana Foundation, National Alliance for Research on Schizophrenia and Depression, National Institutes of Health, National Institute of Mental Health